about
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Transcription factor GATA-1 and Down syndrome leukemogenesisMutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanismsDefective nonhomologous end joining blocks B-cell development in FLT3/ITD miceKnock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse modelMolecular Dynamics Studies on D835N Mutation in FLT3-Its Impact on FLT3 Protein Structure.FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognitionTyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical SignificancemiR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon responseSorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplantPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.The Biology and Targeting of FLT3 in Pediatric Leukemia.Interleukin-3 receptor in acute leukemia.Advances in treating acute myeloid leukemia.FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasmMicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1.Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling.The Future of Targeting FLT3 Activation in AML.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsIncorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.Treatment of FLT3-ITD acute myeloid leukemia.FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoResults from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseNucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemiaUp-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signalingFLT3/ITD AML and the law of unintended consequences.Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignanciesA high-throughput mechanofluidic screening platform for investigating tumor cell adhesion during metastasis.Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
P2860
Q24644436-53003405-9E21-4C1C-AF8F-B003F4AD2C3AQ26992280-5B05C566-E4A6-4417-B658-1C505F8B76DAQ27005960-BD2C6A56-F212-4C8C-828F-5A8408849F06Q27027207-A54A5212-EF4E-47F2-BA81-FEB0C11D1A48Q27028163-F39A562C-905D-4AD4-B140-712C0295431CQ28251869-025E649C-5C92-46E8-B893-5A853500C1D7Q28478611-5BBBB8FF-A4AC-42A3-8D6B-29E732A8D19FQ28506108-5D2DFFB2-E1F2-487E-BA68-C33D5159FADEQ28590872-65CACAF4-24D8-4B3C-A598-1697B3A04966Q30381343-37A9EEE6-9A3E-4538-9606-2BB87F24AC8FQ33680292-87245DEC-F4D2-44AA-BA82-964F4A499C7AQ33761979-B8427EA8-B78A-4BFA-B547-FA303A58CCD7Q33767026-E78690FA-D813-405B-B5D1-EF0F8FB39723Q33778374-BA16DC52-7835-4F77-A470-FDCE8B65FF2FQ33782332-6724CE3E-FCD2-4E69-A597-3FA30A0F1D6DQ34088370-329DBDAE-5225-4263-8B9C-F9B8AC28F81EQ34095013-608EA86A-30EA-4B42-BBEE-3727CC22876CQ34229555-C6D1E225-BC9E-4F24-911E-42506518D7AAQ34283145-F96317FE-AE6D-4CF3-ACCD-847A725E8A85Q34312351-86109AEF-EFDF-46E4-9901-CFB0416A89DCQ34408941-1C3AF4EC-8BB9-477A-9F76-4598BFB64BA9Q34412520-3DCE092D-17BD-41CB-8972-F515AD9A894AQ34507306-17CE7F20-C8F1-42F7-A2BD-B91604DE3696Q34541947-4E8E437C-62FD-4CBA-93DE-0334A87017B7Q34555386-A689C317-45D2-4ADF-B1CB-D540AA308DDDQ34566158-F9874B30-F947-4B78-8DF7-A1304457481DQ34591403-030ECDFD-B0B8-46F9-8FE9-E057A4E462C9Q34620695-48C72CD6-2920-4FD4-A997-5C437F4811A6Q34620761-B76C7AE1-F767-4A34-B1F5-7FFF38D6805AQ34636735-FEDFC784-44CC-4523-8167-79610004B7A8Q34754329-AB78AF05-C72A-4060-91BC-7D7C3488E5CBQ34754344-5777A747-35CE-425F-B985-974355D38CCFQ34755985-7F622C0C-6BDC-471A-AE34-03CE060F53E6Q35006113-E11BAFC8-547D-4B34-A0BF-305C6FAA6336Q35018514-E01038EA-E380-4EB6-9989-CDB1A95CE896Q35127958-E68F825E-AD55-4F39-923E-E8C53EBC72FCQ35525611-CD16BB67-B190-484D-B581-979D575505AEQ35608465-71D3D126-137A-46F2-8785-4CFDF3CA1F4BQ35846178-72CA2267-2AC1-465A-8E3F-A02104A348A7Q35847836-2B3850B3-5ABE-42A2-9CDA-B841E8223397
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
FLT3: ITDoes matter in leukemia.
@ast
FLT3: ITDoes matter in leukemia.
@en
type
label
FLT3: ITDoes matter in leukemia.
@ast
FLT3: ITDoes matter in leukemia.
@en
prefLabel
FLT3: ITDoes matter in leukemia.
@ast
FLT3: ITDoes matter in leukemia.
@en
P2860
P356
P1433
P1476
FLT3: ITDoes matter in leukemia.
@en
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403099
P577
2003-09-01T00:00:00Z